E-4031: Benchmark hERG Potassium Channel Blocker for Cardiac Research

Executive Summary: E-4031 is a potent and selective inhibitor of the hERG potassium channel, with an IC50 of 7.7 nM in vitro (APExBIO product info). It is used to induce QT interval prolongation and torsades de pointes (TdP) in cardiac electrophysiology research (MDV3100 review). E-4031's specificity for the rapid delayed rectifier potassium current (Ikr) in preclinical models makes it essential for proarrhythmic substrate modeling. The compound is stable and highly pure (≥98%) and should be stored at -20°C. APExBIO supplies E-4031 (SKU B6077) for research use, accompanied by rigorous quality control data.

Biological Rationale

The hERG (human Ether-à-go-go-Related Gene) potassium channel regulates cardiac action potential repolarization and underlies the rapid delayed rectifier potassium current (Ikr). Dysfunction or pharmacological blockade of hERG channels leads to delayed repolarization, manifested as QT interval prolongation on the electrocardiogram (ECG) and increased risk for torsades de pointes (TdP), a life-threatening arrhythmia (APExBIO). ATP-sensitive potassium channels, widely expressed in cardiac, muscle, pancreatic beta, and neural tissues, link cellular metabolism to electrical activity. E-4031 targets hERG selectively, providing a controlled means to study the consequences of Ikr inhibition in cardiac electrophysiology research. This selectivity makes E-4031 indispensable for dissecting mechanisms of drug-induced arrhythmias and validating proarrhythmic risk models (CRISPR-CasX review).

Mechanism of Action of E-4031

E-4031 functions as a selective blocker of the hERG potassium channel by binding to the channel pore and inhibiting Ikr current. This blockade prolongs the action potential duration (APD), depolarizes the maximum diastolic potential, and slows the upstroke velocity and diastolic depolarization rate in cardiac myocytes. The effect is dose-dependent and reversible in vitro, with an IC50 of 7.7 nM under standard bath conditions (APExBIO). By inhibiting Ikr, E-4031 delays repolarization, which underlies its ability to generate early afterdepolarizations (EADs) and trigger torsades de pointes during bradycardia or in predisposed models. The compound does not significantly affect other cardiac potassium channels at concentrations ≤100 nM, supporting its utility in mechanistic studies (MDV3100 review).

Evidence & Benchmarks

• E-4031 inhibits human hERG potassium channels with an IC50 of 7.7 nM in patch-clamp assays at 22–25°C, pH 7.4 (APExBIO).
• In vitro, E-4031 prolongs action potential duration and induces early afterdepolarizations (EADs) in isolated cardiac myocytes (Estragolecas article).
• In preclinical animal models, E-4031 prolongs the QT interval and activation-recovery interval (ARI), with the largest effect in the mid-myocardium during bradycardia (CRISPR-CasX review).
• E-4031 does not significantly block other potassium channels (Kv1.5, Kv4.3) at concentrations ≤100 nM (APExBIO).
• APExBIO's E-4031 (SKU B6077) is supplied at ≥98% purity, with HPLC and NMR quality control (APExBIO).

This article extends previous reviews such as "Revolutionizing 3D Cardiac Electrophysiology" by focusing on the quantitative selectivity and storage parameters for E-4031, not covered in detail elsewhere.

Applications, Limits & Misconceptions

E-4031 is used primarily in cardiac electrophysiology research to model drug-induced long QT syndrome (LQTS), study proarrhythmic risk, and validate 3D cardiac organoid models. Its high selectivity for hERG makes it the benchmark for screening new compounds for potential arrhythmogenicity. E-4031 is also utilized for calibrating in vitro and in vivo systems in regulatory safety pharmacology. However, the compound is not approved for clinical use and is strictly for preclinical studies.

Common Pitfalls or Misconceptions

• E-4031 is not a pan-potassium channel blocker; it is highly selective for hERG/Ikr and has minimal effect on other cardiac channels at standard concentrations.
• The compound should not be used for therapeutic antiarrhythmic intervention in humans due to its proarrhythmic risk.
• Storage at -20°C is essential to maintain stability; aqueous solutions are for short-term use only, as degradation may occur.
• Solubility is limited in water; DMSO or ethanol (with warming/sonication) is required for effective dissolution.
• Interpretation of data should consider the model system; effects in rodent models may differ in magnitude from human cardiomyocytes.

Workflow Integration & Parameters

• Preparation: Dissolve E-4031 in DMSO (≥103 mg/mL) or ethanol (≥9.66 mg/mL, with warming/ultrasonication); avoid water as solvent.
• Storage: Store powder at -20°C; use solutions promptly and discard after use.
• Concentration for Ikr inhibition: 10–100 nM in patch-clamp or tissue bath assays; titrate according to cell type and protocol (APExBIO).
• Assay temperature: 22–37°C as required for physiological relevance.
• Compatibility: Suitable for use in 2D/3D cell culture, tissue slices, and animal models.

For a comprehensive protocol and troubleshooting, see this detailed workflow guide, which this article updates by providing precise solubility and storage data.

Conclusion & Outlook

E-4031 remains the gold-standard tool for selective hERG potassium channel blockade and proarrhythmic substrate modeling. Its robust benchmark data and high selectivity make it essential for cardiac electrophysiology research, drug safety screening, and advanced in vitro assay development. However, its proarrhythmic potential restricts use to preclinical models, and results should be interpreted with attention to interspecies and system differences. Ongoing advances in 3D cardiac platforms and high-content screening are likely to further solidify the role of E-4031 in translational research (Estragolecas article).